- Source type
- Government
- Access type
- Official
- Publisher
- U.S. Food and Drug Administration
- Added
- 2026-07-09
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
94
U.S. health regulator
- Publisher type
- Regulator
- Bias profile
- Low
This source is strongest for regulatory status and safety and weaker for consumer context and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 98/100
- Primary Anchor
- Clinical outcomes
- 84/100
- Strong Support
- Mechanism
- 68/100
- Context Source
- Safety
- 95/100
- Primary Anchor
- Consumer context
- 68/100
- Context Source
- Trial discovery
- 68/100
- Context Source
Best used for
- Approvals
- Labels
- Safety communications
Weak for
- Comparative effectiveness
- Consumer experience
Used in Viral Vitalism
Australia's First Child on EB Gene Therapy Is Walking More After Wound Healing
Roles: Regulatory status
Show section-level references
- Jacob Burmeister, a four-year-old in Melbourne with severe epidermolysis bullosa, was reported as the first child in Australia to receive beremagene geperpavec topical gene therapy through one-off access. Reporting says the therapy helped heal a wound present since birth and improved his mobility, but this is a patient-access case, not proof of broad Australian availability or a cure for EB.U.S. regulatory context for the therapy; not proof of Australian routine access.
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: first-in-human EPI-321 study in FSHD
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
UCSF Clinical Trials: NGN-401 Rett syndrome study
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- UCSF Clinical Trials
- Access
- Publisher
- Usage
- 1 connection
EMA: Vyjuvek EPAR
European regulatory context for the therapy; not proof of Australian reimbursement or access.
- Trust score
- 94
- Publisher
- European Medicines Agency
- Access
- Publisher
- Usage
- 1 connection
CIRM: clinical and preclinical development awards
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- CIRM
- Access
- Official
- Usage
- 1 connection
CIRM: more than $60M for clinical and preclinical development awards
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- CIRM
- Access
- Official
- Usage
- 1 connection
FDA clears first over-the-counter continuous glucose monitor
Official FDA clearance source for the OTC CGM boundary: intended population, hypoglycemia limitation, and medical-decision warning.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 7 connections